Expected Moves

Quarterly earnings report evaluating momentum following the massive Q2 print that yielded $28.92 in EPS.

Management update on international distribution agreements and potential tariff impacts on medical testing equipment under President Trump's administration.

Full-year results and strategic outlook on the $3.56B cash pile versus the heavy $21.2B debt load.

Anticipated window for balance sheet restructuring to address portions of the $21.25B debt facility.

First quarter results evaluating baseline revenue run-rates following the normalization of the 2026 testing boom.